Advertisement

Psychotropic Activity of the Antialcohol Preparation Proproten-100

  • E. N. Krylov
Article
  • 31 Downloads

Abstract

Antidepressant Activity of Proproten-100 (antibodies to brain-specific S100 protein in ultralow doses) in patients with stage II alcohol dependence and alcohol withdrawal syndrome was studied in an open comparative clinical trial. The tricyclic antidepressant amitriptyline and benzodiazepine tranquilizer phenazepam served as reference preparations. Anxiolytic activity of Proproten-100 was highly competitive with that of phenazepam. Proproten-100 produced a stronger thymoleptic effect than amitriptyline. The preparation possessed activating properties, affected alcohol addiction, and did not cause side effects. Proproten-100 should undergo clinical tests during the therapy of neurotic, neurosis-like, and subdepressive borderline disorders.

alcohol withdrawal syndrome Proproten-100 antidepressant activity anxiolytic activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    G. Ya. Avrutskii and A. A. Neduva, Therapy of Patients with Mental Disorders [in Russian], Moscow (1988).Google Scholar
  2. 2.
    Yu. V. Valentik and L. M. Savchenko, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 32-35.Google Scholar
  3. 3.
    A. G. Gofman, A. Yu. Magalif, E. N. Krylov, et al., Glossary on Quantitative Analysis of Major Symptoms of Alcoholism. Methodical Recommendations [in Russian], Moscow (1991).Google Scholar
  4. 4.
    A. G. Gofman, A. P. Muzychenko, G. M. Entin, et al., Medicinal Preparations in Clinics of Alcoholism and Drug Addictions. Manual for Physicians [in Russian], Ed. A. Yu. Magalif, Moscow (1999).Google Scholar
  5. 5.
    A. G. Gofman, N. V. Aleksandrova, A. V. Grazhenskii et al., Depressive Disorders in the Structure of Main Symptoms of Alcoholism and Their Therapy. Manual for Physicians [in Russian], Moscow (1999).Google Scholar
  6. 6.
    A. G. Gofman, E. N. Krylov, A. V. Grazhenskii, et al., XIII Convention of Russian Psychiatrists, Moscow (2000), Abstracts of Papers, p. 236.Google Scholar
  7. 7.
    A. G. Gofman, E. N. Krylov, A. V. Grazhenskii, et al., Sots. Klin. Psikhiat., 11,No. 3, 41-43 (2001).Google Scholar
  8. 8.
    A. G. Gofman, E. N. Krylov, A. V. Grazhenskii, et al., New Medicinal Preparations. Express Information [in Russian], Vyp. 2 (2002), pp. 53-58.Google Scholar
  9. 9.
    V. P. Danilin, E. N. Krylov, A. Yu. Magalif, et al., Zh. Nevropatol. Psikhiat., 81,No. 11, 1711-1714 (1981).Google Scholar
  10. 10.
    V. P. Danilin, E. N. Krylov, A. Yu. Magalif, et al., Ibid., 85,No. 2, 263-266 (1985).Google Scholar
  11. 11.
    E. N. Krylov, A. Z. Litvintseva, A. Yu. Magalif, et al., Pathogenesis, Clinics, and Therapy of Alcohol-Associated Diseases [in Russian], Moscow (1984), pp. 19-21.Google Scholar
  12. 12.
    S. N. Mosolov, Antidepressants in Clinical Practice [in Russian], St. Petersburg (1995).Google Scholar
  13. 13.
    M. B. Shtark, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 6-10.Google Scholar
  14. 14.
    G. M. Entin and E. N. Krylov, Clinics and Therapy of Alcohol-Associated Diseases [in Russian], Moscow (1994).Google Scholar
  15. 15.
    O. I. Epstein, Neurophysiological Mechanisms of Pharmacological Effects Produced by Potentiated (Homeopathic) Antibodies to Brain-Specific S100 Protein, Abstract of Cand. Med. Sci. Dissertation, Tomsk (1999).Google Scholar
  16. 16.
    O. I. Epstein, Ultralow Doses of Psychotropic Preparations. VII Russian National Congress “Human and Medicine”, Moscow (2000), Abstracts of Papers, pp. 11-21.Google Scholar
  17. 17.
    M.-A. Crocq, WPA Bull. Depression, 5,No. 23, 3-6 (2001).Google Scholar
  18. 18.
    M. Pottenger, J. McKernon, L. E. Patrie, et al., J. Nerv. Ment. Dis., 166, 562-570 (1978).Google Scholar
  19. 19.
    K. Schapira, M. Roth, T. A. Kerr, et al., Br. J. Psychiatry, 121, 1837-1843 (1972).Google Scholar
  20. 20.
    M. M. Weissman and K. Myers, Am. J. Psychiatry, 137, 372-373 (1980).Google Scholar
  21. 21.
    G. Winokur, Alcoholism and Affective Disorders, Ed. X. Gudwin and X. Erikson, New York (1979), pp. 49-56.Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • E. N. Krylov
    • 1
  1. 1.Moscow Institute of PsychiatryRussian Ministry of HealthRussia

Personalised recommendations